Dyax's mission is to discover, develop, and commercialize innovative biopharmaceuticals for unmet medical needs while delivering outstanding value to patients and stockholders.
At the core of our success is our powerful and proprietary drug discovery technology, phage display. This technology provides us a unique advantage of being able to identify and develop our own clinical leads to fuel our internal pipeline. We also leverage phage display into licenses and collaborations with companies and researchers interested in furthering their own pipelines.
Our work is driven by one unifying factor that motivates us all: our patients.
Our Areas of Focus:
- KALBITOR® (ecallantide) Discovered and developed by Dyax, KALBITOR is the Company’s lead product and is approved in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. To find out more and to see Important Safety Information and Full Prescribing Information, including Boxed Warning and Medication Guide, visit www.KALBITOR.com.
- Expanding the Angioedema Portfolio We are dedicated to identifying and developing treatments for patients who experience plasma kallikrein (bradykinin) mediated angioedema.
- Licensing and Funded Research Program (LFRP) We develop our proprietary phage display libraries and discovery capabilities available to partners and collaborators through revenue-generating licenses. Under this extensive licensing program, partners can benefit from the same technology we apply to our own clinical development pursuits.